Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arovella Therapeutics Limited ( (AU:ALA) ) has shared an update.
Arovella Therapeutics has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its lead allogeneic CAR-iNKT cell therapy candidate, ALA-101, targeting CD19-positive non-Hodgkin’s lymphoma and leukaemias. Clearance of the application would enable the company to launch a first-in-human Phase 1 trial in relapsed or refractory CD19-positive blood cancers, with trial sites planned in both Australia and the United States under a more efficient regulatory pathway, marking Arovella’s transition toward becoming a clinical-stage biotech and potentially strengthening its position in the competitive cell therapy market.
More about Arovella Therapeutics Limited
Arovella Therapeutics Limited is an ASX-listed biotechnology company developing an invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers and solid tumours. Its lead product, ALA-101, is an allogeneic CAR-iNKT cell therapy targeting the CD19 antigen found on various haematological malignancies, and the company is also expanding into solid tumour therapies using CLDN18.2-targeting and IL-12-TM technologies.
Average Trading Volume: 1,205,507
Technical Sentiment Signal: Sell
Current Market Cap: A$92.49M
Find detailed analytics on ALA stock on TipRanks’ Stock Analysis page.